Curis Inc. filings document the regulatory record of a biotechnology company focused on emavusertib (CA-4948) and related oncology-development activities. Form 8-K disclosures cover financial results, clinical and regulatory updates, material agreements, capital-structure matters and Nasdaq listing-compliance notices.
Proxy and other filings describe shareholder voting matters, authorized-share proposals, securities issuances tied to preferred stock and warrant instruments, equity incentive plans, executive compensation and governance procedures. The filing record also includes pro forma financial information related to the completed sale of the company’s interest in Curis Royalty, LLC.
CURIS INC CFO Diantha Duvall received an employee stock option grant covering 48,285 shares of common stock at an exercise price of $5.29 per share. This is a compensation-related award, not an open-market stock purchase or sale.
The option vests over time, with 25% of the original shares vesting on July 7, 2027, and an additional 6.25% vesting each quarter until July 7, 2030. The option expires on July 6, 2036 if not exercised.
CURIS INC Chief Development Officer Jonathan B. Zung received a grant of employee stock options covering 48,285 shares of common stock at an exercise price of $5.29 per share. These options expire on July 6, 2036 and represent his entire reported option position in this filing.
The grant vests over time. According to the terms, 25% of the original option shares vest on July 7, 2027, with an additional 6.25% vesting each successive quarter until July 7, 2030. This structure ties a significant portion of his compensation to the company’s long-term stock performance.
CURIS INC President & CEO James E. Dentzer reported a compensation-related grant of employee stock options. He was awarded options to buy 110,090 shares of Curis common stock at an exercise price of $5.29 per share, expiring on July 6, 2036.
According to the filing, 25% of the original option shares vest on July 7, 2027, with an additional 6.25% of the original shares vesting each successive quarter until July 7, 2030. Following this grant, Dentzer holds options covering 110,090 underlying shares directly.
Curis, Inc. implemented a 1-for-20 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern Time on July 2, 2026. Every 20 issued and outstanding shares of common stock are being converted into one share, with fractional shares rounded up to the nearest whole share.
The reverse split does not change the $0.01 par value or the number of authorized common shares. All outstanding warrants, restricted stock units, stock options and the share reserves under equity incentive plans will be proportionally adjusted. Trading on a split-adjusted basis will begin July 6, 2026, and the stock will continue under the ticker “CRIS” with a new CUSIP 231269408.
Curis, Inc. filed an amended report to update timing details for its previously approved reverse stock split. The Reverse Stock Split Certificate of Amendment is expected to become effective on July 2, 2026 at 5:00 PM ET. Curis common stock is expected to begin trading on The Nasdaq Stock Market on a split-adjusted basis at market open on July 6, 2026. The shares will continue to trade under the ticker symbol “CRIS”, and the common stock will have a new CUSIP number following the reverse split.
Curis, Inc. is implementing a reverse stock split of its common stock at a 1-for-20 ratio. This means every 20 existing shares will be combined into 1 share, reducing the number of shares outstanding while proportionally increasing the price per share.
At a special meeting of stockholders held on June 25, 2026, stockholders approved amendments to the Restated Certificate of Incorporation allowing a reverse split in a range between 1-for-5 and 1-for-25. On the same date, the Board of Directors chose the specific 1-for-20 ratio.
Curis, Inc. held a special stockholder meeting on June 25, 2026, where investors approved a reverse stock split authorization. Stockholders adopted amendments to the Restated Certificate of Incorporation allowing the Board to implement a reverse split of the common stock at a ratio between 1-for-5 and 1-for-25, with discretion to choose the exact ratio or abandon the change.
The reverse split proposal received 26,898,163 votes for, 751,966 against, and 123,820 abstentions. A separate proposal to adjourn the meeting, if needed to secure additional votes, also passed but was not used.
Curis, Inc. is asking stockholders at a virtual special meeting on June 25, 2026 to approve amendments allowing a reverse stock split of its common stock at a ratio between 1‑for‑5 and 1‑for‑25, to be chosen later by the board within six months.
The main goal is to increase the share price to meet Nasdaq Capital Market bid‑price requirements after receiving a Nasdaq delisting determination for trading below the $1.00 minimum. The board argues a higher price could help preserve the listing and broaden institutional interest, though it warns the split may not sustain a higher price and could reduce liquidity and create odd lots.
The reverse split would not change total authorized shares of 567,514,300, would affect all stockholders proportionally, and fractional shares would be rounded up to the nearest whole share. A second proposal would allow the meeting to be adjourned to solicit more proxies if needed. As of May 21, 2026, 38,978,693 common shares were outstanding and entitled to vote.
Curis, Inc. is asking stockholders to approve amendments to its Restated Certificate of Incorporation to permit a reverse stock split of its common stock at a ratio set by the Board between 1-for-5 and 1-for-25. If approved, the Board may implement the Reverse Stock Split at any time within six months following stockholder approval or abandon it before filing.
The Special Meeting is virtual on June 25, 2026 (record date: May 21, 2026), and 38,978,693 shares were outstanding as of the record date. Proposal 2 would permit adjournment to solicit additional proxies. The Board recommends a FOR vote on both proposals.
Curis, Inc. reported that stockholders approved a major amendment to its charter to increase total authorized capital stock from 288,757,150 to 572,514,300 shares, including an increase in authorized common stock from 283,757,150 to 567,514,300 shares. The amendment became effective upon filing in Delaware.
The company also filed a Certificate of Elimination to remove the designations for its Series A Convertible Exchangeable Preferred Stock and Series B Convertible Non-Redeemable Preferred Stock, returning those shares to undesignated preferred stock. At the same annual meeting, two Class III directors were re-elected, executive compensation received majority support in a nonbinding vote, and PricewaterhouseCoopers LLP was ratified as independent auditor for the 2026 fiscal year.